Global Oncology Academy

Poster Pearl: Examining Systemic Therapy for BPDCN While Also Treating or Prophylaxing CNS Involvement with IT Chemotherapy

ReachMD Healthcare Image
RestartResume

Dive into the findings and implications of a poster that was presented at the 2022 European Hematology Association Annual Congress.

Take Post-Survey

If you’ve already completed the activity.

  • Overview

    A recent study sought to determine whether CNS treatment or prophylaxis combined with systemic tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN) impacts patient prognosis and the efficacy of tagraxofusp. According to the results presented as a poster at the 2022 European Hematology Association Annual Congress, treatment with tagraxofusp and intrathecal chemotherapy was associated with promising efficacy in patients with CNS disease, with no unexpected safety events. Joining Dr. Charles Turck to share the key findings and how they may impact the way we approach treating patients with BPDCN is Dr. Justin Taylor, Assistant Professor of Hematology at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free